Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus coagulans SNZ 1969
- Development stage
- Unknown
- Lead developer
- Sanzyme Biologics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans SNZ 1969 is a proprietary, spore-forming probiotic strain developed and manufactured by Sanzyme Biologics. Originally introduced to the Indian market in 1972 as SPORLAC, it was the first probiotic sold in India. As a spore-former, the strain is naturally resilient to gastric acid and bile, allowing it to reach the intestines where it germinates and exerts its effects. Its primary mechanism involves modulating the gut-immune axis, specifically by enhancing natural killer (NK) cell activity and increasing mucosal immunoglobulin A (IgA) levels, thereby supporting both innate and adaptive immunity. Clinically, it has been studied for its efficacy in improving gastrointestinal health—including symptoms of irritable bowel syndrome (IBS-C and IBS-D)—and for its role in supporting immune health in both adults and children.
- Brand names
- SPORLACSPORLAC DSSPORLAC PLUS
- Other names
- B. coagulans SNZ 1969
02
Targets
IgA (Immunoglobulin A)
Beyond the preview
Go deeper on Bacillus coagulans SNZ 1969.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacillus coagulans SNZ 1969.